Literature DB >> 31258162

Compliance with Recommended Practices for Management of Controlled Substances in a Health Care Facility and Corrective Actions.

Manon Videau1, Suzanne Atkinson2, Maxime Thibault3, Denis Lebel2, Jean-François Bussières4.   

Abstract

BACKGROUND: Pharmacists are required to maintain a secure inventory of medications and to ensure proper, safe, and diversion-free dispensing practices.
OBJECTIVES: The primary objectives of this study were to determine compliance with recommended practices for the management of controlled substances in a mother-child teaching hospital and to identify actions to improve compliance. The secondary objective was to identify steps in the drug pathway for controlled substances and associated failure modes in the study hospital.
METHODS: This descriptive cross-sectional study used a framework developed by the California Hospital Association (CHA) to assess compliance with recommended practices for the management of controlled substances in hospitals. For each criterion, a research assistant observed practices within the pharmacy, on patient care units, at outpatient care clinics, and in operating and delivery rooms. The level of compliance was recorded as compliant, partially compliant, or noncompliant. An Ishikawa diagram was developed to illustrate steps in the drug pathway and associated failure modes related to the use of controlled substances in the study hospital.
RESULTS: The pathway for controlled substances at the study hospital was compliant for 56 (49.6%) of the 113 CHA criteria, partially compliant for 27 (23.9%) of the criteria, and noncompliant for 24 (21.2%) of the criteria; the remaining 6 (5.3%) criteria were not applicable. This practice evaluation highlighted 22 corrective actions, 12 (55%) that could be implemented in the short term, 8 (36%) suitable for implementation in the medium term, and 2 (9%) suitable for both the short and medium term. A total of 57 potential failure modes related to the use of controlled substances were identified.
CONCLUSIONS: The pathway for controlled substances at the study hospital was compliant with almost half of the CHA criteria, and 22 corrective actions were identified. Pharmacists, physicians, and nurses should be mobilized to optimize the use of controlled substances throughout the drug-use process.

Entities:  

Keywords:  controlled substances; drug diversion; management audit; practice guidelines

Year:  2018        PMID: 31258162      PMCID: PMC6592654     

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


  11 in total

1.  Prescription opioid abuse: what is the real problem and how do we fix it?

Authors:  M E Lynch; Benedikt Fischer
Journal:  Can Fam Physician       Date:  2011-11       Impact factor: 3.275

2.  Development of a computerized monitoring program to identify narcotic diversion in a pediatric anesthesia practice.

Authors:  B Randall Brenn; Margaret A Kim; Elora Hilmas
Journal:  Am J Health Syst Pharm       Date:  2015-08-15       Impact factor: 2.637

3.  Compliance with recommendations for prevention and detection of controlled-substance diversion in hospitals.

Authors:  Steven R McClure; Brian C O'Neal; Dennis Grauer; Rick J Couldry; Allison R King
Journal:  Am J Health Syst Pharm       Date:  2011-04-15       Impact factor: 2.637

4. 

Authors:  Sophie Dubois; Emmy Bernier; Julie Rivard; Lavina Yu; Suzanne Atkinson; Jean-François Bussières
Journal:  Can J Hosp Pharm       Date:  2017-04-28

Review 5.  ASHP Guidelines on Preventing Diversion of Controlled Substances.

Authors:  Philip W Brummond; David F Chen; William W Churchill; John S Clark; Kevin R Dillon; Doina Dumitru; Lynn Eschenbacher; Toni Fera; Christopher R Fortier; Kristine K Gullickson; Kristen Jurakovich; Stan Kent; Jennifer Keonavong; Christine Marchese; Tricia Meyer; Lee B Murdaugh; Richard K Ogden; Brian C O'Neal; Steve Rough; Rafael Saenz; Jacob S Smith
Journal:  Am J Health Syst Pharm       Date:  2017-01-04       Impact factor: 2.637

6.  Trends in high-dose opioid prescribing in Canada.

Authors:  Tara Gomes; Muhammad M Mamdani; J Michael Paterson; Irfan A Dhalla; David N Juurlink
Journal:  Can Fam Physician       Date:  2014-09       Impact factor: 3.275

Review 7.  Impaired healthcare professional.

Authors:  Marie R Baldisseri
Journal:  Crit Care Med       Date:  2007-02       Impact factor: 7.598

Review 8.  Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations.

Authors:  Shannon M Smith; Richard C Dart; Nathaniel P Katz; Florence Paillard; Edgar H Adams; Sandra D Comer; Aldemar Degroot; Robert R Edwards; David J Haddox; Jerome H Jaffe; Christopher M Jones; Herbert D Kleber; Ernest A Kopecky; John D Markman; Ivan D Montoya; Charles O'Brien; Carl L Roland; Marsha Stanton; Eric C Strain; Gary Vorsanger; Ajay D Wasan; Roger D Weiss; Dennis C Turk; Robert H Dworkin
Journal:  Pain       Date:  2013-06-20       Impact factor: 6.961

9.  Diversion of drugs within health care facilities, a multiple-victim crime: patterns of diversion, scope, consequences, detection, and prevention.

Authors:  Keith H Berge; Kevin R Dillon; Karen M Sikkink; Timothy K Taylor; William L Lanier
Journal:  Mayo Clin Proc       Date:  2012-07       Impact factor: 7.616

10.  Controlled Substance Reconciliation Accuracy Improvement Using Near Real-Time Drug Transaction Capture from Automated Dispensing Cabinets.

Authors:  Richard H Epstein; Franklin Dexter; David M Gratch; Michael Perino; Jerry Magrann
Journal:  Anesth Analg       Date:  2016-06       Impact factor: 5.108

View more
  3 in total

1. 

Authors:  Clarence Chant
Journal:  Can J Hosp Pharm       Date:  2018-06-30

2.  Diversion Inattention: Time for Action!

Authors:  Clarence Chant
Journal:  Can J Hosp Pharm       Date:  2018-06-30

3.  Vulnerabilities for Drug Diversion in the Handling, Data Entry, and Verification Tasks of 2 Inpatient Hospital Pharmacies: Clinical Observations and Healthcare Failure Mode and Effect Analysis.

Authors:  Maaike de Vries; Mark Fan; Dorothy Tscheng; Michael Hamilton; Patricia Trbovich
Journal:  J Patient Saf       Date:  2022-01-01       Impact factor: 2.844

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.